Oxidized Low-Density Lipoprotein/β2-Glycoprotein I Complexes and Autoantibodies to oxLig-1/β2-Glycoprotein I in Patients with Systemic Lupns Erythematosus and Antiphospholipid Syndrome

Daniel Lopez, Ignacio Garcia-Valladares, Claudia A. Palafox-Sanchez, Ignacio Garcia De La Torre, Kazuko Kobayashi, Eiji Matsuura, Luis R. Lopez

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Oxidized low-density lipoprotein (oxLDL) interacts with β 2-glycoprotein I (β2-GPI) via oxLDL-derived specific ligands (oxLig-1) forming complexes. The prevalence and significance of oxLDL/β2-GPI complexes and antibodies to oxLig-1/β 2-GPI were evaluated in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). The oxLDL/β2-GPI complex was 69% positive (above mean + 3 SD of control subjects) in 97 consecutive patients with SLE, 62% in 40 patients with SLE with secondary APS, and 60% in 50 control patients with SLE without APS. IgG anti-oxLig-1/β 2-GPI antibody was positive in 31 (32%) of 97 consecutive patients with SLE, in 26 (65%) of 40 patients with SLE with secondary APS, and in 6 (19%) of 32 control patients with SLE. Anti-oxLig-1/β2-GPI antibodies were 93.7% specific with a positive predictive value of 90.0% for APS, better than anticardiolipin antibodies (80.0% specific, 71.4% predictive value). These results confirm that oxLDL/β2-GPI complexes are common in SLE and suggest a possible immunogenic role in APS. In contrast, IgG anti-oxLig-1/β2-GPI antibodies not only are associated with but also are clinically useful risk factors for APS.

Original languageEnglish
Pages (from-to)426-436
Number of pages11
JournalAmerican Journal of Clinical Pathology
Volume121
Issue number3
DOIs
Publication statusPublished - Mar 2004

Fingerprint

Antiphospholipid Syndrome
LDL Lipoproteins
Systemic Lupus Erythematosus
Autoantibodies
Glycoproteins
Antibodies
Anticardiolipin Antibodies
oxidized low density lipoprotein
7-ketocholesteryl-9-carboxynonanoate
Ligands

Keywords

  • Antiphospholipid antibodies
  • Autoimmunity
  • Oxidized-LDL antibodies

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Oxidized Low-Density Lipoprotein/β2-Glycoprotein I Complexes and Autoantibodies to oxLig-1/β2-Glycoprotein I in Patients with Systemic Lupns Erythematosus and Antiphospholipid Syndrome. / Lopez, Daniel; Garcia-Valladares, Ignacio; Palafox-Sanchez, Claudia A.; De La Torre, Ignacio Garcia; Kobayashi, Kazuko; Matsuura, Eiji; Lopez, Luis R.

In: American Journal of Clinical Pathology, Vol. 121, No. 3, 03.2004, p. 426-436.

Research output: Contribution to journalArticle

@article{5d74e5341bf8445ca5bce064af6dbb0e,
title = "Oxidized Low-Density Lipoprotein/β2-Glycoprotein I Complexes and Autoantibodies to oxLig-1/β2-Glycoprotein I in Patients with Systemic Lupns Erythematosus and Antiphospholipid Syndrome",
abstract = "Oxidized low-density lipoprotein (oxLDL) interacts with β 2-glycoprotein I (β2-GPI) via oxLDL-derived specific ligands (oxLig-1) forming complexes. The prevalence and significance of oxLDL/β2-GPI complexes and antibodies to oxLig-1/β 2-GPI were evaluated in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). The oxLDL/β2-GPI complex was 69{\%} positive (above mean + 3 SD of control subjects) in 97 consecutive patients with SLE, 62{\%} in 40 patients with SLE with secondary APS, and 60{\%} in 50 control patients with SLE without APS. IgG anti-oxLig-1/β 2-GPI antibody was positive in 31 (32{\%}) of 97 consecutive patients with SLE, in 26 (65{\%}) of 40 patients with SLE with secondary APS, and in 6 (19{\%}) of 32 control patients with SLE. Anti-oxLig-1/β2-GPI antibodies were 93.7{\%} specific with a positive predictive value of 90.0{\%} for APS, better than anticardiolipin antibodies (80.0{\%} specific, 71.4{\%} predictive value). These results confirm that oxLDL/β2-GPI complexes are common in SLE and suggest a possible immunogenic role in APS. In contrast, IgG anti-oxLig-1/β2-GPI antibodies not only are associated with but also are clinically useful risk factors for APS.",
keywords = "Antiphospholipid antibodies, Autoimmunity, Oxidized-LDL antibodies",
author = "Daniel Lopez and Ignacio Garcia-Valladares and Palafox-Sanchez, {Claudia A.} and {De La Torre}, {Ignacio Garcia} and Kazuko Kobayashi and Eiji Matsuura and Lopez, {Luis R.}",
year = "2004",
month = "3",
doi = "10.1309/2AUE-6HD4-W6TL-EUU5",
language = "English",
volume = "121",
pages = "426--436",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Oxidized Low-Density Lipoprotein/β2-Glycoprotein I Complexes and Autoantibodies to oxLig-1/β2-Glycoprotein I in Patients with Systemic Lupns Erythematosus and Antiphospholipid Syndrome

AU - Lopez, Daniel

AU - Garcia-Valladares, Ignacio

AU - Palafox-Sanchez, Claudia A.

AU - De La Torre, Ignacio Garcia

AU - Kobayashi, Kazuko

AU - Matsuura, Eiji

AU - Lopez, Luis R.

PY - 2004/3

Y1 - 2004/3

N2 - Oxidized low-density lipoprotein (oxLDL) interacts with β 2-glycoprotein I (β2-GPI) via oxLDL-derived specific ligands (oxLig-1) forming complexes. The prevalence and significance of oxLDL/β2-GPI complexes and antibodies to oxLig-1/β 2-GPI were evaluated in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). The oxLDL/β2-GPI complex was 69% positive (above mean + 3 SD of control subjects) in 97 consecutive patients with SLE, 62% in 40 patients with SLE with secondary APS, and 60% in 50 control patients with SLE without APS. IgG anti-oxLig-1/β 2-GPI antibody was positive in 31 (32%) of 97 consecutive patients with SLE, in 26 (65%) of 40 patients with SLE with secondary APS, and in 6 (19%) of 32 control patients with SLE. Anti-oxLig-1/β2-GPI antibodies were 93.7% specific with a positive predictive value of 90.0% for APS, better than anticardiolipin antibodies (80.0% specific, 71.4% predictive value). These results confirm that oxLDL/β2-GPI complexes are common in SLE and suggest a possible immunogenic role in APS. In contrast, IgG anti-oxLig-1/β2-GPI antibodies not only are associated with but also are clinically useful risk factors for APS.

AB - Oxidized low-density lipoprotein (oxLDL) interacts with β 2-glycoprotein I (β2-GPI) via oxLDL-derived specific ligands (oxLig-1) forming complexes. The prevalence and significance of oxLDL/β2-GPI complexes and antibodies to oxLig-1/β 2-GPI were evaluated in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). The oxLDL/β2-GPI complex was 69% positive (above mean + 3 SD of control subjects) in 97 consecutive patients with SLE, 62% in 40 patients with SLE with secondary APS, and 60% in 50 control patients with SLE without APS. IgG anti-oxLig-1/β 2-GPI antibody was positive in 31 (32%) of 97 consecutive patients with SLE, in 26 (65%) of 40 patients with SLE with secondary APS, and in 6 (19%) of 32 control patients with SLE. Anti-oxLig-1/β2-GPI antibodies were 93.7% specific with a positive predictive value of 90.0% for APS, better than anticardiolipin antibodies (80.0% specific, 71.4% predictive value). These results confirm that oxLDL/β2-GPI complexes are common in SLE and suggest a possible immunogenic role in APS. In contrast, IgG anti-oxLig-1/β2-GPI antibodies not only are associated with but also are clinically useful risk factors for APS.

KW - Antiphospholipid antibodies

KW - Autoimmunity

KW - Oxidized-LDL antibodies

UR - http://www.scopus.com/inward/record.url?scp=1542317794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542317794&partnerID=8YFLogxK

U2 - 10.1309/2AUE-6HD4-W6TL-EUU5

DO - 10.1309/2AUE-6HD4-W6TL-EUU5

M3 - Article

C2 - 15023048

AN - SCOPUS:1542317794

VL - 121

SP - 426

EP - 436

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -